Comparison of ED50 of norepinephrine during the treatment of postspinal hypotension in patients with pregnancy-induced hypertension at different stress hormone levels: a randomized controlled dose-response study using up-down sequential allocation method

A study of the effect of stress hormone levels on ED50 of norepinephrine during the treatment of postspinal hypotension in patients with pregnancy-induced hypertension Comparison of ED50 of norepinephrine during the treatment of postspinal hypotension in patients with pregnancy-induced hypertension at different stress hormone levels: a randomized controlled dose-response study using up-down sequential allocation method

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300077891

Enrollment

Unknown

Registered

2023-11-23

Start date

2023-11-25

Completion date

Unknown

Last updated

2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension

Interventions

Group GH:norepinephrine 3-7ug

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Singleton pregnancy who scheduled for elective cesarean section and received combined spinal-epidural anesthesia; ASA Level 2-3; Aged 18-40. PIH is defined as a woman whose blood pressure was normal before pregnancy and whose blood pressure was measured at least 4 hours apart on two or more separate occasions after pregnancy, with a systolic blood pressure (SBP) of 140 mmHg and/or diastolic blood pressure (DBP) of 90 mmHg

Exclusion criteria

Exclusion criteria: 1. Patients with chronic hypertension, diabetes and serious cardiovascular and cerebrovascular diseases; 2. Patients with known fetal abnormalities or intrauterine growth restriction; 3. Patients with obstetric complications include premature rupture of membranes, placenta previa and placental abruption; 4. Those who have contraindications to intraspinal anesthesia or research related drugs; 5. The patient's clinical ASA grade is more than 3; 6. The height is too high or too low (>180 cm or<150 cm); 7. Gestational age<28 weeks.

Design outcomes

Primary

Measure	Time frame
Norepinephrine dose;Stress hormone levels ;	—

Secondary

Measure	Time frame
blood pressure; Heart Rate;Age;weight;height;Anesthesia induction-delivery time;Uterine incision-delivery time;	—

Countries

China

Contacts

Public ContactFeng Fu

Women's Hospital, Zhejiang University School of Medicine

fufeng@zju.edu.cn+86 135 8839 2113

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026